Current Status of all Claims

Claims 1-24 are cancelled.

25. (New) A conjugate comprising Substance P, or an analog thereof, and a polypeptide that inhibits protein synthesis, wherein the analog is selected from CYGGGGGGRPKPQQFF SarLMet(O2)-amide (SEQ ID NO:1) and CYGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).

26. (New) The conjugate of claim 25, wherein said analog of Substance P comprises the amino acid sequence CYGGGGGGRPKPQQFF SarLMet(O2)-amide (SEQ ID NO:1).

27. (New) The conjugate of claim 25, wherein said analog of Substance P comprises the amino acid sequence CYGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).

28. (New) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is attached to said Substance P or analog thereof through a disulfide linkage.

29. (New) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is saporin.

30. (New) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is a ribosome-inactivating protein.

31. (New) The conjugate of claim 30, wherein said ribosome-inactivating protein is selected from ricin A chain, gelonin and pokeweed antiviral protein.

32. (New) The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is a toxin.

33. (New) The conjugate of claim 32, wherein said toxin is diphtheria toxin A fragment or an analog thereof that inhibits protein synthesis.

34. (New) The conjugate of claim 32, wherein said toxin is pseudomonas aeruginosa exotoxin A fragment or an analog thereof that inhibits protein synthesis.

35. (New) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 25, and a pharmaceutically acceptable carrier.

36. (New) A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 29, and a pharmaceutically acceptable carrier.